Johnson & Johnson announced the launch of four of its prescription medications—Invokamet, Invokamet XR, Invokana, and Xarelto—on the Trump administration’s TrumpRx website and on its own JNJ Direct platform. The partnership includes a three‑year exemption from a 100% statutory tariff on patented drugs manufactured outside the United States and requires the company to adopt most‑favored‑nation pricing, aligning U.S. prices with those in other developed markets.
The move broadens J&J’s reach to cash‑paying patients and those whose insurance does not cover the drugs, while reinforcing the company’s strategy to grow direct‑to‑consumer sales. By offering the drugs on TrumpRx, J&J can tap a new customer base that has historically faced higher out‑of‑pocket costs, and the tariff exemption reduces the cost of imported active ingredients, improving margin potential.
J&J’s Q1 2026 results provide context for the launch. Revenue rose 9.9% to $24.1 billion, driven by strong demand in its Innovative Medicine and MedTech segments, and adjusted earnings per share reached $2.70, beating the consensus estimate of $2.66. The beat reflects disciplined cost management and a favorable product mix, while the company raised its full‑year 2026 guidance to $100.8 billion in sales and $11.55 in adjusted EPS, signaling confidence in continued growth.
Chief Executive Officer Joaquin Duato said, “Today's agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy.” He added that the company’s “strong start to 2026” and its “relentless focus on innovation” underpin the decision to expand access through TrumpRx.
The launch fits a broader industry trend of direct‑to‑consumer platforms, with peers such as Pfizer and Eli Lilly also moving in that direction. J&J has committed $55 billion to U.S. manufacturing, research, and development through 2029, including new facilities in North Carolina and Pennsylvania. While the company faces a headwind from the patent expiration of Stelara, which saw sales fall from $1.6 billion in Q1 2025 to $656 million in Q1 2026, its strong performance in other product lines and the new distribution channel help offset that decline.
Overall, the TrumpRx partnership represents a strategic effort to broaden access to key diabetes and anticoagulation therapies while positioning J&J to capture a growing segment of the U.S. market that prefers direct purchase. Coupled with robust quarterly results and an upward revision of full‑year guidance, the move underscores the company’s commitment to growth and resilience amid evolving market dynamics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.